Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 16/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 16/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 16/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 16/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23920869 | 0.94 | TDP1 (0.53) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24775863 | 0.92 | TDP1 (0.54) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23921230 | 0.92 | TDP1 (0.54) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23921234 | 0.92 | TDP1 (0.56) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23921142 | 0.92 | TDP1 (0.53) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23921218 | 0.91 | TDP1 (0.53) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23921153 | 0.89 | TDP1 (0.51) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23920868 | 0.88 | TDP1 (0.56) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24775992 | 0.87 | TDP1 (0.57) | TDP1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL24775103 | 0.87 | TDP1 (0.58) | TDP1ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317156-A1 | NEW POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317156-A1 | NEW POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PDE7A | TDP1 690/4885PDE4A 12/4885PDE4B 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.